相关实验视频

Updated: Jun 30, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

用阿比拉酸盐治疗高风险转移性化敏感前列腺癌患者的骨修饰剂

Wataru Fukuokaya¹, Keiichiro Mori¹, Fumihiko Urabe¹

¹Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

JAMA network open

|March 15, 2024

概括

骨修饰剂 (BMA) 改善了转移性割敏感前列腺癌 (mCSPC) 患者的骨相关事件的时间. BMA的使用可能有利于mCSPC患者接受抗雄激素剥夺疗法 (ADT),有或没有abiraterone酸盐加上前素 (AAP).

科学领域:

在瘤学瘤学.
前列腺癌研究研究前列腺癌
药理干预药理干预

背景情况:

骨修饰剂 (BMA) 在转移性割敏感前列腺癌 (mCSPC) 治疗与阿比拉酸加普得尼松 (AAP) 中的作用尚不清楚.
了解BMA的影响对于优化高风险mCSPC患者的治疗策略至关重要.

研究的目的:

调查BMA使用与接受AAP的mCSPC患者的临床结果之间的关联.
评估BMAs对骨相关事件 (SREs) 和整体存活率 (OS) 的影响.

主要方法:

从第3阶段LATITUDE试验中对个体参与者数据的后期分析.
包括接受AAP和雄激素剥夺疗法 (ADT) 或安慰剂和ADT的高风险mCSPC患者.
被定义为双酸盐或代诺苏马布的BMA在随机化后90天内被施用;使用治疗权重的逆概率 (IPTW) 和Cox回归来评估结果.

主要成果:

在AAP队列中,BMA使用与SRE更长的时间相关 (差距7.8个月),但不是OS.
在ADT队列中,BMA使用与SRE (9.3个月的差异) 和OS (5.5个月的差异) 的较长时间有关.
在BMA使用和AAP或ADT治疗之间没有发现SRE或OS的显著相互作用.

结论:

在接受ADT治疗的高风险mCSPC患者中,BMA使用与SRE的延长时间有关,而不管AAP是否添加.
对于接受ADT的mCSPC患者来说,BMA可能会给骨带来好处.
进一步的研究可能会澄清BMAs在晚期前列腺癌组合治疗中的作用.

更多相关视频

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...